NO311302B1 - Fremgangsmåte for å amplifisere et target RNA segment - Google Patents

Fremgangsmåte for å amplifisere et target RNA segment Download PDF

Info

Publication number: NO311302B1
Authority: NO; Norway
Prior art keywords: rna; dna; sequence; target; nucleic acid
Prior art date: 1988-12-16

Application number

NO19912328A

Other languages

English (en)

Norwegian (no)

Other versions

NO912328D0 (no

NO912328L (no

Inventor

Thomas Raymond Gingeras

John C Guatelli

Kristina Marie Whitfield

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-12-16

Filing date

1991-06-17

Publication date

2001-11-12

1991-06-17 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

1991-06-17 Publication of NO912328D0 publication Critical patent/NO912328D0/no

1991-06-17 Publication of NO912328L publication Critical patent/NO912328L/no

2001-11-12 Publication of NO311302B1 publication Critical patent/NO311302B1/no

Links

238000000034 method Methods 0.000 title claims description 55
150000007523 nucleic acids Chemical class 0.000 claims abstract description 96
108020004414 DNA Proteins 0.000 claims abstract description 76
102000039446 nucleic acids Human genes 0.000 claims abstract description 64
108020004707 nucleic acids Proteins 0.000 claims abstract description 64
230000003321 amplification Effects 0.000 claims abstract description 44
238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 44
238000006243 chemical reaction Methods 0.000 claims abstract description 38
102000053602 DNA Human genes 0.000 claims abstract description 24
238000009396 hybridization Methods 0.000 claims abstract description 23
102100034343 Integrase Human genes 0.000 claims description 44
102000004190 Enzymes Human genes 0.000 claims description 43
108090000790 Enzymes Proteins 0.000 claims description 43
102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 30
108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 30
230000000694 effects Effects 0.000 claims description 29
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 24
101710203526 Integrase Proteins 0.000 claims description 21
230000001419 dependent effect Effects 0.000 claims description 18
230000000295 complement effect Effects 0.000 claims description 17
238000005520 cutting process Methods 0.000 claims description 15
238000013518 transcription Methods 0.000 claims description 14
230000035897 transcription Effects 0.000 claims description 14
230000015572 biosynthetic process Effects 0.000 claims description 12
239000011541 reaction mixture Substances 0.000 claims description 12
108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 7
241000588724 Escherichia coli Species 0.000 claims description 7
102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 6
239000001226 triphosphate Substances 0.000 claims description 6
235000011178 triphosphate Nutrition 0.000 claims description 5
108020004682 Single-Stranded DNA Proteins 0.000 claims description 4
238000004458 analytical method Methods 0.000 claims description 4
230000008569 process Effects 0.000 claims description 4
241001515965 unidentified phage Species 0.000 claims description 4
238000004925 denaturation Methods 0.000 claims description 3
230000036425 denaturation Effects 0.000 claims description 3
NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 claims description 2
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 2
238000010924 continuous production Methods 0.000 claims description 2
239000005549 deoxyribonucleoside Substances 0.000 claims description 2
239000002853 nucleic acid probe Substances 0.000 claims description 2
239000002342 ribonucleoside Substances 0.000 claims description 2
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 claims description 2
241000713869 Moloney murine leukemia virus Species 0.000 claims 1
241001430294 unidentified retrovirus Species 0.000 claims 1
239000013615 primer Substances 0.000 abstract description 66
108091028043 Nucleic acid sequence Proteins 0.000 abstract description 38
238000001514 detection method Methods 0.000 abstract description 30
238000004519 manufacturing process Methods 0.000 abstract description 18
239000003153 chemical reaction reagent Substances 0.000 abstract description 10
239000003155 DNA primer Substances 0.000 abstract description 6
108020001019 DNA Primers Proteins 0.000 abstract description 3
230000006862 enzymatic digestion Effects 0.000 abstract 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 98
239000000523 sample Substances 0.000 description 33
108091034117 Oligonucleotide Proteins 0.000 description 31
239000000047 product Substances 0.000 description 26
241000713772 Human immunodeficiency virus 1 Species 0.000 description 20
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 15
230000027455 binding Effects 0.000 description 13
101710137500 T7 RNA polymerase Proteins 0.000 description 11
239000000203 mixture Substances 0.000 description 11
230000037452 priming Effects 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
108010026228 mRNA guanylyltransferase Proteins 0.000 description 9
239000002299 complementary DNA Substances 0.000 description 7
230000010076 replication Effects 0.000 description 7
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
102000040650 (ribonucleotides)n+m Human genes 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
238000010348 incorporation Methods 0.000 description 6
PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
239000002773 nucleotide Substances 0.000 description 6
239000002987 primer (paints) Substances 0.000 description 6
241000894007 species Species 0.000 description 6
238000007792 addition Methods 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000000872 buffer Substances 0.000 description 5
238000013213 extrapolation Methods 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
238000012360 testing method Methods 0.000 description 5
241000700605 Viruses Species 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
230000001351 cycling effect Effects 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
229940124276 oligodeoxyribonucleotide Drugs 0.000 description 4
239000012071 phase Substances 0.000 description 4
238000003752 polymerase chain reaction Methods 0.000 description 4
238000007363 ring formation reaction Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
239000013616 RNA primer Substances 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
230000009471 action Effects 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
229960002685 biotin Drugs 0.000 description 3
235000020958 biotin Nutrition 0.000 description 3
239000011616 biotin Substances 0.000 description 3
210000001124 body fluid Anatomy 0.000 description 3
239000010839 body fluid Substances 0.000 description 3
230000002255 enzymatic effect Effects 0.000 description 3
238000002955 isolation Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
238000005259 measurement Methods 0.000 description 3
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 3
-1 nucleoside triphosphate Chemical class 0.000 description 3
239000008188 pellet Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
DEQPBRIACBATHE-FXQIFTODSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-2-iminopentanoic acid Chemical compound N1C(=O)N[C@@H]2[C@H](CCCC(=N)C(=O)O)SC[C@@H]21 DEQPBRIACBATHE-FXQIFTODSA-N 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
241000701832 Enterobacteria phage T3 Species 0.000 description 2
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
108060004795 Methyltransferase Proteins 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
102000006382 Ribonucleases Human genes 0.000 description 2
108010083644 Ribonucleases Proteins 0.000 description 2
208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 2
206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 2
108700009124 Transcription Initiation Site Proteins 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
230000000692 anti-sense effect Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000000975 dye Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
239000012139 lysis buffer Substances 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
102000004196 processed proteins & peptides Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
238000011160 research Methods 0.000 description 2
238000000926 separation method Methods 0.000 description 2
125000006850 spacer group Chemical group 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
238000011282 treatment Methods 0.000 description 2
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
239000003656 tris buffered saline Substances 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
108020003215 DNA Probes Proteins 0.000 description 1
239000003298 DNA probe Substances 0.000 description 1
108010067770 Endopeptidase K Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
208000031220 Hemophilia Diseases 0.000 description 1
208000009292 Hemophilia A Diseases 0.000 description 1
101000899111 Homo sapiens Hemoglobin subunit beta Proteins 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
101710086015 RNA ligase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241001468001 Salmonella virus SP6 Species 0.000 description 1
108091081021 Sense strand Proteins 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
238000002105 Southern blotting Methods 0.000 description 1
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 1
RJUXXNSHJWNJBM-UHFFFAOYSA-N [Cl-].[Cs+].[N-]=C=S.NC([NH3+])=N Chemical compound [Cl-].[Cs+].[N-]=C=S.NC([NH3+])=N RJUXXNSHJWNJBM-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000012620 biological material Substances 0.000 description 1
238000010804 cDNA synthesis Methods 0.000 description 1
229910052792 caesium Inorganic materials 0.000 description 1
TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
238000006555 catalytic reaction Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
241001493065 dsRNA viruses Species 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
239000012634 fragment Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
238000003505 heat denaturation Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
229910001629 magnesium chloride Inorganic materials 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000002609 medium Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
150000008300 phosphoramidites Chemical class 0.000 description 1
108060006184 phycobiliprotein Proteins 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000000163 radioactive labelling Methods 0.000 description 1
238000004064 recycling Methods 0.000 description 1
230000003252 repetitive effect Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
229920002477 rna polymer Polymers 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000008685 targeting Effects 0.000 description 1
239000003104 tissue culture media Substances 0.000 description 1
230000005026 transcription initiation Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/702—Specific hybridization probes for retroviruses
- C12Q1/703—Viruses associated with AIDS
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6865—Promoter-based amplification, e.g. nucleic acid sequence amplification [NASBA], self-sustained sequence replication [3SR] or transcription-based amplification system [TAS]

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Immunology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biophysics (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
Biomedical Technology (AREA)
AIDS & HIV (AREA)
Chemical Kinetics & Catalysis (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Detergent Compositions (AREA)
Exchange Systems With Centralized Control (AREA)
Error Detection And Correction (AREA)
Electrotherapy Devices (AREA)
Enzymes And Modification Thereof (AREA)
Saccharide Compounds (AREA)
Optical Communication System (AREA)
Reverberation, Karaoke And Other Acoustics (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Cosmetics (AREA)
Apparatus Associated With Microorganisms And Enzymes (AREA)

NO19912328A 1988-12-16 1991-06-17 Fremgangsmåte for å amplifisere et target RNA segment NO311302B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US28546788A	1988-12-16	1988-12-16
PCT/US1989/005631 WO1990006995A1 (en)	1988-12-16	1989-12-14	Self-sustained sequence replication system

Publications (3)

Publication Number	Publication Date
NO912328D0 NO912328D0 (no)	1991-06-17
NO912328L NO912328L (no)	1991-06-17
NO311302B1 true NO311302B1 (no)	2001-11-12

Family

ID=23094358

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19912328A NO311302B1 (no)	1988-12-16	1991-06-17	Fremgangsmåte for å amplifisere et target RNA segment

Country Status (20)

Country	Link
EP (2)	EP0778352A1 (ko)
JP (1)	JP3152927B2 (ko)
KR (1)	KR0148265B1 (ko)
AT (1)	ATE156192T1 (ko)
AU (2)	AU4829690A (ko)
BR (1)	BR8907830A (ko)
CA (1)	CA2005589C (ko)
DE (1)	DE68928222T2 (ko)
DK (1)	DK175630B1 (ko)
ES (1)	ES2107412T3 (ko)
FI (1)	FI99143C (ko)
GR (1)	GR3024403T3 (ko)
HU (1)	HU216105B (ko)
IL (2)	IL92732A (ko)
NO (1)	NO311302B1 (ko)
NZ (1)	NZ231815A (ko)
PT (1)	PT92602B (ko)
RU (1)	RU2107729C1 (ko)
WO (1)	WO1990006995A1 (ko)
ZA (1)	ZA899593B (ko)

Families Citing this family (175)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5753433A (en) *	1909-12-05	1998-05-19	Boehringer Mannheim Gmbh	Method for the sensitive detection of nucleic acids
CA1340807C (en) *	1988-02-24	1999-11-02	Lawrence T. Malek	Nucleic acid amplification process
JP2650159B2 (ja) *	1988-02-24	1997-09-03	アクゾ・ノベル・エヌ・ベー	核酸増幅方法
US5130238A (en) *	1988-06-24	1992-07-14	Cangene Corporation	Enhanced nucleic acid amplification process
US6589734B1 (en)	1989-07-11	2003-07-08	Gen-Probe Incorporated	Detection of HIV
US7009041B1 (en)	1989-07-11	2006-03-07	Gen-Probe Incorporated	Oligonucleotides for nucleic acid amplification and for the detection of Mycobacterium tuberculosis
US5766849A (en) *	1989-07-11	1998-06-16	Gen-Probe Incorporated	Methods of amplifying nucleic acids using promoter-containing primer sequence
CA2020958C (en) *	1989-07-11	2005-01-11	Daniel L. Kacian	Nucleic acid sequence amplification methods
KR100242252B1 (ko) *	1989-07-11	2000-03-02	다니엘 엘. 캐시앙	핵산서열의 증폭방법
WO1991004340A1 (en) *	1989-09-20	1991-04-04	Cambridge Biotech Corporation	In vitro, isothermal nucleic acid amplification
US5545522A (en) *	1989-09-22	1996-08-13	Van Gelder; Russell N.	Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US7049102B1 (en)	1989-09-22	2006-05-23	Board Of Trustees Of Leland Stanford University	Multi-gene expression profile
EP0540693B1 (en) *	1990-07-24	1999-01-20	F. Hoffmann-La Roche Ag	THE REDUCTION OF NON-SPECIFIC AMPLIFICATION DURING $i(IN VITRO) NUCLEIC ACID AMPLIFICATION USING MODIFIED NUCLEIC ACID BASES
IL100040A (en) *	1990-11-13	1995-12-31	Siska Diagnostics Inc	Amplification of nucleic acids by replicating a self-sustaining enzymatic sequence
CA2095611A1 (en) *	1990-11-14	1992-05-15	Jennifer Kyoko Ishii	Non-isotopic detection of nucleic acids using a polystyrene support-based sandwich hybridization assay and compositions useful therefor
JP3183510B2 (ja) *	1990-12-31	2001-07-09	プロメガ・コーポレイシヨン	Ｒｎａレプリカーゼのｄｎａ依存性ｒｎａポリメラーゼ活性を用いる核酸増幅
AU8997991A (en) *	1991-01-31	1992-08-06	Becton Dickinson & Company	Exonuclease mediated strand displacement amplification
WO1992020820A1 (en) *	1991-05-15	1992-11-26	Vanderbilt University	Method to determine metastatic potential of tumor cells
ATE257860T1 (de) *	1991-08-02	2004-01-15	Biomerieux Bv	Quantifikation von nukleinsäuren
DE4129653A1 (de) *	1991-09-06	1993-03-11	Boehringer Mannheim Gmbh	Verfahren zum nachweis aehnlicher nukleinsaeuren
DE4213029A1 (de) *	1991-09-26	1993-04-01	Boehringer Mannheim Gmbh	Verfahren zur spezifischen vervielfaeltigung von nukleins aeuresequenzen
DE4132133A1 (de) *	1991-09-26	1993-04-01	Boehringer Mannheim Gmbh	Verfahren zur spezifischen herstellung von ribonukleinsaeuren
WO1993022461A1 (en) *	1992-05-06	1993-11-11	Gen-Probe Incorporated	Nucleic acid sequence amplification method, composition and kit
US5843640A (en) *	1992-06-19	1998-12-01	Northwestern University	Method of simultaneously detecting amplified nucleic acid sequences and cellular antigens in cells
AU686616B2 (en)	1993-03-26	1998-02-12	Gen-Probe Incorporated	Detection of human immunodeficiency virus type 1
US5814442A (en) *	1994-06-10	1998-09-29	Georgetown University	Internally controlled virion nucleic acid amplification reaction for quantitation of virion and virion nucleic acid
FR2724934B1 (fr) *	1994-09-26	1997-01-24	Bio Merieux	Oligonucleotide chimere et son utilisation dans l'obtention de transcrits d'un acide nucleique
FR2726277B1 (fr)	1994-10-28	1996-12-27	Bio Merieux	Oligonucleotide utilisable comme amorce dans une methode d'amplification basee sur une replication avec deplacement de brin
US5770368A (en) *	1996-05-09	1998-06-23	Metropolitan Water District Of Southern California	Cryptosporidium detection method
US6436638B1 (en)	1996-05-09	2002-08-20	Metropolitan Water District Of Southern California	Cryptosporidium detection method
US6235479B1 (en)	1999-04-13	2001-05-22	Bio Merieux, Inc.	Methods and devices for performing analysis of a nucleic acid sample
AT410218B (de)	1999-08-20	2003-03-25	Baxter Ag	Verfahren zur herstellung eines qualitätsgesicherten pools biologischer proben
US6893847B2 (en)	2001-01-17	2005-05-17	Tosoh Corporation	Oligonucleotide for detecting Salmonella and method of detecting Salmonella
US7338805B2 (en)	2001-05-04	2008-03-04	Bio Merieux	Labeling reagents, methods for synthesizing such reagents and methods for detecting biological molecules
US7504215B2 (en)	2002-07-12	2009-03-17	Affymetrix, Inc.	Nucleic acid labeling methods
TW200413527A (en)	2002-10-29	2004-08-01	Riken	Amplification of nucleic acid
FR2855832B1 (fr)	2003-06-03	2007-09-14	Biomerieux Sa	Procede de diagnostic et/ou de pronostic d'un syndrome septique
WO2005000098A2 (en)	2003-06-10	2005-01-06	The Trustees Of Boston University	Detection methods for disorders of the lung
FR2857375B1 (fr)	2003-07-10	2007-11-09	Biomerieux Sa	Procede de detection et/ou d'identification de bacteries de genre staphylococcus
US8173785B2 (en)	2003-11-26	2012-05-08	Advandx, Inc.	Peptide nucleic acid probes for analysis of certain Staphylococcus species
TW201037080A (en)	2003-12-25	2010-10-16	Danform Kk	Method of amplifying nucleic acid and method of detecting mutated nucleic acid using the same
CA2497324A1 (en)	2004-02-17	2005-08-17	Affymetrix, Inc.	Methods for fragmenting and labelling dna
FR2868071B1 (fr)	2004-03-26	2006-06-09	Biomerieux Sa	Reactifs de marquage, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
FR2868433B1 (fr)	2004-04-06	2008-01-18	Biomerieux Sa	Procede pour le pronostic et/ou le diagnostic d'un cancer
EP1647600A3 (en)	2004-09-17	2006-06-28	Affymetrix, Inc. (A US Entity)	Methods for identifying biological samples by addition of nucleic acid bar-code tags
US20060073511A1 (en)	2004-10-05	2006-04-06	Affymetrix, Inc.	Methods for amplifying and analyzing nucleic acids
EP1652580A1 (en)	2004-10-29	2006-05-03	Affymetrix, Inc.	High throughput microarray, package assembly and methods of manufacturing arrays
US7682782B2 (en)	2004-10-29	2010-03-23	Affymetrix, Inc.	System, method, and product for multiple wavelength detection using single source excitation
FR2881437B1 (fr)	2005-01-31	2010-11-19	Biomerieux Sa	Procede pour le diagnostic/pronostic d'un syndrome septique
EP1874955A4 (en)	2005-02-28	2009-05-06	Bioquest Inc	METHODS FOR EXECUTING DIRECT ENZYMATIC REACTIONS USING NUCLEIC ACID MOLECULES
EP3211093A1 (en)	2005-04-14	2017-08-30	The Trustees of Boston University	Diagnostic for lung disorders using class prediction
JP2008539766A (ja)	2005-05-17	2008-11-20	オズジーンプロプライアタリーリミテッド	連続的クローニング系
FR2886735B1 (fr)	2005-06-01	2015-09-11	Biomerieux Sa	Procede de marquage ou de traitement d'un echantillon biologique contenant des molecules biologiques d'interet, notamment des acides nucleiques
US7550264B2 (en)	2005-06-10	2009-06-23	Datascope Investment Corporation	Methods and kits for sense RNA synthesis
FR2902430B1 (fr)	2005-11-25	2012-11-02	Biomerieux Sa	Oligonucleotides, utilisation, methode de detection et kit permettant de diagnostiquer la presence des genes h5 et n1 du virus d'influenza a
CA2645310A1 (en)	2006-03-09	2007-09-13	The Trustees Of Boston University	Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
US20120196827A1 (en)	2006-06-12	2012-08-02	Oncomethylome Sciences S.A.	Methylation markers for early detection and prognosis of colon cancers
AU2007284651B2 (en)	2006-08-09	2014-03-20	Institute For Systems Biology	Organ-specific proteins and methods of their use
FR2906537A1 (fr)	2006-09-28	2008-04-04	Biomerieux Sa	Procede de diagnostic in vitro du cancer broncho-pulmonaire par detection des transcrits majoritaires alternatifs du gene klk8 codant la kallicreine 8 et son utilisation pour le pronostic de survie
US9845494B2 (en)	2006-10-18	2017-12-19	Affymetrix, Inc.	Enzymatic methods for genotyping on arrays
JP2010508815A (ja)	2006-11-02	2010-03-25	イエール・ユニバーシテイ	卵母細胞受容能の評価
US8293684B2 (en)	2006-11-29	2012-10-23	Exiqon	Locked nucleic acid reagents for labelling nucleic acids
GB0701253D0 (en)	2007-01-23	2007-02-28	Diagnostics For The Real World	Nucleic acid amplification and testing
EP1956097A1 (en)	2007-02-06	2008-08-13	bioMerieux B.V.	Method for discriminating single nucleotide polymorphisms (SNPs)
FR2917090B1 (fr)	2007-06-11	2012-06-15	Biomerieux Sa	Reactifs de marquage portant des fonctions diazo et nitro, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
JP2009000063A (ja)	2007-06-22	2009-01-08	Tosoh Corp	改良されたノロウイルスｒｎａ検出方法
EP2179052B1 (en)	2007-07-09	2012-11-14	Microsens Medtech Ltd	Detection of micro-organisms based on their nad-dependent dna ligase activity
EP2201131B8 (en)	2007-09-17	2014-12-10	MDxHealth SA	Improved methylation detection
EP3147375A1 (en)	2007-09-17	2017-03-29	MDxHealth SA	Novel markers for bladder cancer detection
JPWO2009044773A1 (ja)	2007-10-04	2011-02-10	東ソー株式会社	レジオネラ属菌ｒＲＮＡ増幅用プライマー、検出方法および検出キット
EP2071034A1 (en)	2007-12-12	2009-06-17	bioMérieux	Method for treating a solution in order to destroy any ribonucleic acid after amplification
EP2677041A3 (en)	2008-02-19	2014-04-09	MDxHealth SA	Detection and prognosis of lung cancer
EP2626435B1 (en)	2008-03-21	2016-06-01	MDxHealth S.A.	Detection and prognosis of cervical cancer
FR2934595B1 (fr)	2008-07-29	2013-04-05	Biomerieux Sa	Reactifs de marquage ayant un noyau pyridine portant une fonction diazomethyle, procedes de synthese de tels reactifs et procedes de detection de molecules biologiques
CA2679750A1 (en)	2008-09-23	2010-03-23	Nexus Dx, Inc.	Methods for detecting nucleic acids in a sample
EP2172563A1 (en)	2008-09-24	2010-04-07	bioMérieux S.A.	Method for lowering the dependency towards sequence variation of a nucleic acid target in a diagnostic hybridization assay
JP5428272B2 (ja)	2008-10-06	2014-02-26	東ソー株式会社	サバイビンｍＲＮＡの測定方法
FR2940805B1 (fr)	2009-01-05	2015-10-16	Biomerieux Sa	Procede d'amplification et/ou de detection d'acides nucleiques, kits et utilisations de ce procede
WO2010082004A1 (fr)	2009-01-19	2010-07-22	Biomerieux	Procedes pour determiner la susceptibilite a contracter une infection nosocomiale chez un patient et pour etablir un pronostic d'evolution d'un syndrome septique
US20120164238A1 (en)	2009-02-03	2012-06-28	Mdxhealth Sa	Methods of detecting colorectal cancer
EP2396661A4 (en)	2009-02-11	2013-10-30	Caris Mpi Inc	MOLECULAR PROFILING OF TUMORS
CA2755358A1 (en)	2009-03-13	2010-09-16	Mdxhealth Sa	Novel markers for bladder cancer detection
CN102575284A (zh)	2009-03-17	2012-07-11	MDx健康公司	改进的基因表达检测
CN102858995B (zh)	2009-09-10	2016-10-26	森特瑞隆技术控股公司	靶向测序方法
US10174368B2 (en)	2009-09-10	2019-01-08	Centrillion Technology Holdings Corporation	Methods and systems for sequencing long nucleic acids
FR2950358B1 (fr)	2009-09-18	2015-09-11	Biomerieux Sa	Dispositif d'amplification d'acides nucleiques simplifie et son procede de mise en oeuvre
WO2011036173A1 (en)	2009-09-24	2011-03-31	Oncomethylome Sciences S.A.	Detection and prognosis of cervical cancer
CA2779223A1 (en)	2009-10-27	2011-05-12	Caris Mpi, Inc.	Molecular profiling for personalized medicine
US8835358B2 (en)	2009-12-15	2014-09-16	Cellular Research, Inc.	Digital counting of individual molecules by stochastic attachment of diverse labels
TWI518325B (zh)	2010-02-04	2016-01-21	自治醫科大學	對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
WO2011135058A2 (en)	2010-04-30	2011-11-03	Mdxhealth Sa	Methods for detecting epigenetic modifications
KR101176139B1 (ko)	2010-05-20	2012-08-22	광주과학기술원	관절염 동물모델로서 연골 특이적 ＨＩＦ?２α 형질전환 마우스 및 이의 용도
KR101223660B1 (ko)	2010-05-20	2013-01-17	광주과학기술원	ＨＩＦ－２α 억제제를 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물
EP2576815B1 (en)	2010-06-04	2018-02-14	Biomérieux	Method for the prognosis of colorectal cancer
US11031095B2 (en)	2010-08-06	2021-06-08	Ariosa Diagnostics, Inc.	Assay systems for determination of fetal copy number variation
US8700338B2 (en)	2011-01-25	2014-04-15	Ariosa Diagnosis, Inc.	Risk calculation for evaluation of fetal aneuploidy
US20140342940A1 (en)	2011-01-25	2014-11-20	Ariosa Diagnostics, Inc.	Detection of Target Nucleic Acids using Hybridization
US20130261003A1 (en)	2010-08-06	2013-10-03	Ariosa Diagnostics, In.	Ligation-based detection of genetic variants
US20130040375A1 (en)	2011-08-08	2013-02-14	Tandem Diagnotics, Inc.	Assay systems for genetic analysis
US10533223B2 (en)	2010-08-06	2020-01-14	Ariosa Diagnostics, Inc.	Detection of target nucleic acids using hybridization
US20120034603A1 (en)	2010-08-06	2012-02-09	Tandem Diagnostics, Inc.	Ligation-based detection of genetic variants
US10167508B2 (en)	2010-08-06	2019-01-01	Ariosa Diagnostics, Inc.	Detection of genetic abnormalities
US11203786B2 (en)	2010-08-06	2021-12-21	Ariosa Diagnostics, Inc.	Detection of target nucleic acids using hybridization
WO2012024642A1 (en)	2010-08-20	2012-02-23	Life Technologies Corporation	Quantitative real-time pcr assay using fret dual-labeled primers
US9110079B2 (en)	2010-09-29	2015-08-18	Biomerieux	Method and kit for establishing an in vitro prognosis on a patient exhibiting SIRS
US9994897B2 (en)	2013-03-08	2018-06-12	Ariosa Diagnostics, Inc.	Non-invasive fetal sex determination
US11270781B2 (en)	2011-01-25	2022-03-08	Ariosa Diagnostics, Inc.	Statistical analysis for non-invasive sex chromosome aneuploidy determination
US20120190020A1 (en)	2011-01-25	2012-07-26	Aria Diagnostics, Inc.	Detection of genetic abnormalities
US10131947B2 (en)	2011-01-25	2018-11-20	Ariosa Diagnostics, Inc.	Noninvasive detection of fetal aneuploidy in egg donor pregnancies
FR2970975B1 (fr)	2011-01-27	2016-11-04	Biomerieux Sa	Procede et kit pour determiner in vitro le statut immunitaire d'un individu
CN103562407A (zh)	2011-02-09	2014-02-05	伯乐生命医学产品有限公司	核酸的分析
CA2827200A1 (en)	2011-02-24	2012-08-30	Hill's Pet Nutrition, Inc.	Compositions and methods for diagnosing and treating kidney disorders in a feline
WO2012118745A1 (en)	2011-02-28	2012-09-07	Arnold Oliphant	Assay systems for detection of aneuploidy and sex determination
WO2012129758A1 (en)	2011-03-25	2012-10-04	Biomerieux	Method and kit for determining in vitro probability for individual to suffer from colorectal cancer
US20120252682A1 (en)	2011-04-01	2012-10-04	Maples Corporate Services Limited	Methods and systems for sequencing nucleic acids
KR101291668B1 (ko)	2011-04-21	2013-08-01	서울대학교산학협력단	미코박테리아―대장균용 셔틀 벡터 및 이의 용도
EP2721175B1 (en)	2011-06-15	2015-09-16	Hill's Pet Nutrition, Inc.	Compositions and methods for diagnosing and monitoring hyperthyroidism in a feline
AU2012272908A1 (en)	2011-06-21	2013-12-19	Alnylam Pharmaceuticals, Inc.	Assays and methods for determining activity of a therapeutic agent in a subject
WO2013024175A2 (en)	2011-08-17	2013-02-21	Technische Universität München	Diagnostic means and methods for type 2 diabetes
GB201206209D0 (en)	2012-04-06	2012-05-23	Univ Leuven Kath	Marker gene based diagnosis, staging and prognosis of prostate caner
FR2981088B1 (fr)	2011-10-06	2013-11-29	Biomerieux Sa	Arn polymerases mutees
WO2013095935A1 (en)	2011-12-19	2013-06-27	Hill's Pet Nutrition, Inc.	Compositions and methods for diagnosing and treating hyperthyroidism in companion animals
GB2504240B (en)	2012-02-27	2015-05-27	Cellular Res Inc	Compositions and kits for molecular counting of nucleic acids
WO2013130512A2 (en)	2012-02-27	2013-09-06	The University Of North Carolina At Chapel Hill	Methods and uses for molecular tags
EP4148142A1 (en)	2012-05-21	2023-03-15	The Scripps Research Institute	Methods of sample preparation
US10289800B2 (en)	2012-05-21	2019-05-14	Ariosa Diagnostics, Inc.	Processes for calculating phased fetal genomic sequences
AU2013292287A1 (en)	2012-07-19	2015-02-19	Ariosa Diagnostics, Inc.	Multiplexed sequential ligation-based detection of genetic variants
FR3000966B1 (fr)	2013-01-11	2016-10-28	Biomerieux Sa	Procede pour etablir in vitro un pronostic de severite chez un patient en choc septique
KR101403507B1 (ko)	2013-03-21	2014-06-09	주식회사 현일바이오	결핵균 및 비결핵 마이코박테리아의 선택적 검출 방법, 그리고 이를 이용한 키트
KR101507505B1 (ko)	2013-04-18	2015-04-07	사회복지법인 삼성생명공익재단	제 1 형 근긴장성 이영양증의 진단 방법
US10072300B2 (en)	2013-05-21	2018-09-11	Biomerieux	Kit for the prognosis of colorectal cancer
EP3663414B1 (en)	2013-06-13	2023-11-22	Roche Diagnostics GmbH	Statistical analysis for non-invasive y chromosome aneuploidy determination
US9547006B2 (en)	2013-08-08	2017-01-17	Institut Pasteur	Correlation of disease activity with clonal expansions of human papillomavirus 16-specific CD8+ T-cells in patients with severe erosive oral lichen planus
ES2857908T3 (es)	2013-08-28	2021-09-29	Becton Dickinson Co	Análisis masivamente paralelo de células individuales
ES2720728T3 (es)	2013-11-15	2019-07-24	Pasteur Institut	Un marcador molecular de Plasmodium falciparum de resistencia a artemisinina
GB201322034D0 (en)	2013-12-12	2014-01-29	Almac Diagnostics Ltd	Prostate cancer classification
ES2880335T3 (es)	2014-09-09	2021-11-24	Igenomx Int Genomics Corporation	Métodos y composiciones para la preparación rápida de bibliotecas de ácidos nucleicos
KR101718800B1 (ko)	2015-01-21	2017-03-24	주식회사 디알나노	약물 및 ｓｉＲＮＡ의 공동―운반용 나노복합체 및 이의 용도
GB201510684D0 (en)	2015-06-17	2015-08-05	Almac Diagnostics Ltd	Gene signatures predictive of metastatic disease
US20180305748A1 (en)	2015-10-18	2018-10-25	Affymetrix, Inc.	Multiallelic Genotyping of Single Nucleotide Polymorphisms and Indels
KR101651817B1 (ko)	2015-10-28	2016-08-29	대한민국	Ngs 라이브러리 제작용 프라이머 세트 및 이를 이용한 ngs 라이브러리 제작방법 및 키트
KR101845957B1 (ko)	2016-02-23	2018-04-05	전남대학교기술지주회사(주)	프로히비틴 유전자 타깃 백혈병 진단용 키트 및 이를 이용한 진단 방법
GB201605110D0 (en)	2016-03-24	2016-05-11	Mologic Ltd	Detecting sepsis
MA45934A (fr)	2016-08-10	2019-06-19	Centre Nat Rech Scient	Procédés et réactifs utilisés pour la détection du paludisme à plasmodium falciparum résistant à la pipéraquine
KR101936799B1 (ko)	2017-01-09	2019-01-11	주식회사 엠이티라이프사이언스	구강전암의 치료용 약학 조성물 및 구강전암 또는 구강암의 예측 또는 진단 방법
WO2018202864A1 (fr)	2017-05-05	2018-11-08	bioMérieux	Procédé de détection d'une réponse cellulaire immune
EP3631008A1 (en)	2017-06-02	2020-04-08	Affymetrix, Inc.	Array-based methods for analysing mixed samples using differently labelled allele-specific probes
US11441174B2 (en)	2017-06-02	2022-09-13	Affymetrix, Inc.	Array-based methods for analysing mixed samples using differently labelled allele-specific probes
WO2019017680A2 (ko)	2017-07-19	2019-01-24	국민대학교 산학협력단	파킨슨병 바이오마커로서의 miRNA 및 이를 이용한 진단키트
KR101956315B1 (ko)	2017-07-19	2019-03-08	국민대학교 산학협력단	파킨슨병 바이오마커로서의 miR494 및 이를 이용한 진단키트
WO2019094578A1 (en)	2017-11-09	2019-05-16	Alnylam Pharmaceuticals Inc.	Assays and methods for determining expression of the lect2 gene
FR3080185A1 (fr)	2018-04-16	2019-10-18	Biomerieux	Evaluation du risque de complication chez un patient suspecte d'avoir une infection ayant un score sofa inferieur a deux
FR3085689A1 (fr)	2018-09-12	2020-03-13	Biomerieux	Procede pour determiner in vitro ou ex vivo le statut immunitaire d'un individu
EP3814532A1 (fr)	2018-06-29	2021-05-05	bioMérieux	Procédé pour déterminer in vitro ou ex vivo le statut immunitaire d'un individu
EP3888021B1 (en)	2018-11-30	2024-02-21	Caris MPI, Inc.	Next-generation molecular profiling
GB201902458D0 (en)	2019-02-22	2019-04-10	Mologic Ltd	Treatment stratification for an excerbation of inflamation
EP3708678A1 (en)	2019-03-15	2020-09-16	Adisseo France S.A.S.	Process for identifying a stress state in a subject
US20220220564A1 (en)	2019-04-17	2022-07-14	Igenomix, S.L.	Improved methods for the early diagnosis of uterine leiomyomas and leiomyosarcomas
FR3101358A1 (fr)	2019-09-27	2021-04-02	Bioaster	Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
CN114729402A (zh)	2019-10-01	2022-07-08	生物梅里埃公司	用于确定个体对刺激物作出反应的能力的方法
FR3101423A1 (fr)	2019-10-01	2021-04-02	bioMérieux	Procédé pour déterminer la capacité d’un individu à répondre à un stimulus
GB201914538D0 (en)	2019-10-08	2019-11-20	Momentum Bioscience Ltd	Microorganism capture from antimicrobial-containing solution
KR20220130108A (ko)	2019-12-02	2022-09-26	캐리스 엠피아이, 아이엔씨.	범-암 백금 반응 예측기
EP4163397A4 (en)	2020-06-05	2024-08-28	Seegene Inc	SAMPLE TRANSPORT KIT FOR THE DETECTION OF RESPIRATORY PATHOGENS AND METHODS FOR THE DETECTION OF RESPIRATORY PATHOGENS THEREOF
FR3112210A1 (fr)	2020-07-06	2022-01-07	bioMérieux	Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112211A1 (fr)	2020-07-06	2022-01-07	bioMérieux	Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112207A1 (fr)	2020-07-06	2022-01-07	bioMérieux	Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112208A1 (fr)	2020-07-06	2022-01-07	bioMérieux	Procédé pour déterminer le risque de survenue d’une infection associée aux soins chez un patient
FR3112209A1 (fr)	2020-07-06	2022-01-07	bioMérieux	Procédé pour déterminer le risque de complication chez un patient
WO2022106795A1 (fr)	2020-11-20	2022-05-27	bioMérieux	Procédé de classification d'un individu
FR3125065A1 (fr)	2021-07-08	2023-01-13	bioMérieux	Procédé et kit de détection d’un virus respiratoire réplicatif
KR20240090267A (ko)	2021-10-29	2024-06-21	주식회사 씨젠	검체 채취 스왑 도구 및 호흡기 병원체의 검출 방법
FR3139579A1 (fr)	2022-09-09	2024-03-15	bioMérieux	Procédé de détection in vitro ou ex vivo d’un statut immunodéprimé chez un sujet
WO2024110392A1 (en)	2022-11-22	2024-05-30	bioMérieux	New nucleic acid binding compounds and uses
WO2024170798A1 (fr)	2023-02-17	2024-08-22	Naos Institute Of Life Science	Procede de selection d'un compose ecobiologique apte a augmenter le seuil de tolerance de la peau

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4520110A (en)	1981-10-06	1985-05-28	The Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing a phycobiliprotein labeled ligand or receptor
EP0128042A3 (en)	1983-06-06	1985-01-16	Genentech, Inc.	A process for indentifying or isolating a dna sequence, and a dna hybridization probe therefor
CA1288073C (en)	1985-03-07	1991-08-27	Paul G. Ahlquist	Rna transformation vector
DK171161B1 (da)	1985-03-28	1996-07-08	Hoffmann La Roche	Fremgangsmåde til påvisning af forekomst eller fravær af mindst én specifik nukleinsyresekvens i en prøve eller til skelnen mellem to forskellige nukleinsyresekvenser i denne prøve
US4683202A (en) *	1985-03-28	1987-07-28	Cetus Corporation	Process for amplifying nucleic acid sequences
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
IL86724A (en)	1987-06-19	1995-01-24	Siska Diagnostics Inc	Methods and kits for amplification and testing of nucleic acid sequences
AU618965B2 (en) *	1987-07-31	1992-01-16	Board Of Trustees Of The Leland Stanford Junior University	Selective amplification of target polynucleotide sequences
CA1340843C (en) *	1987-07-31	1999-12-07	J. Lawrence Burg	Selective amplification of target polynucleotide sequences
CA1340807C (en) *	1988-02-24	1999-11-02	Lawrence T. Malek	Nucleic acid amplification process
GB9807888D0 (en)	1998-04-09	1998-06-10	Chirotech Technology Ltd	Asymmetric hydrogenation

1989
- 1989-12-14 AU AU48296/90A patent/AU4829690A/en not_active Abandoned
- 1989-12-14 ZA ZA899593A patent/ZA899593B/xx unknown
- 1989-12-14 KR KR1019900701772A patent/KR0148265B1/ko not_active IP Right Cessation
- 1989-12-14 JP JP50187990A patent/JP3152927B2/ja not_active Expired - Lifetime
- 1989-12-14 BR BR898907830A patent/BR8907830A/pt not_active IP Right Cessation
- 1989-12-14 RU SU4895764A patent/RU2107729C1/ru active
- 1989-12-14 WO PCT/US1989/005631 patent/WO1990006995A1/en active IP Right Grant
- 1989-12-14 HU HU1165/90A patent/HU216105B/hu unknown
- 1989-12-14 CA CA002005589A patent/CA2005589C/en not_active Expired - Lifetime
- 1989-12-15 ES ES89313154T patent/ES2107412T3/es not_active Expired - Lifetime
- 1989-12-15 IL IL92732A patent/IL92732A/xx not_active IP Right Cessation
- 1989-12-15 EP EP97100006A patent/EP0778352A1/en not_active Withdrawn
- 1989-12-15 DE DE68928222T patent/DE68928222T2/de not_active Expired - Lifetime
- 1989-12-15 AT AT89313154T patent/ATE156192T1/de not_active IP Right Cessation
- 1989-12-15 PT PT92602A patent/PT92602B/pt not_active IP Right Cessation
- 1989-12-15 EP EP89313154A patent/EP0373960B1/en not_active Expired - Lifetime
- 1989-12-15 NZ NZ231815A patent/NZ231815A/xx unknown
1991
- 1991-06-11 DK DK199101106A patent/DK175630B1/da not_active IP Right Cessation
- 1991-06-14 FI FI912885A patent/FI99143C/fi active
- 1991-06-17 NO NO19912328A patent/NO311302B1/no not_active IP Right Cessation
1994
- 1994-05-10 AU AU63013/94A patent/AU675520B2/en not_active Expired
1995
- 1995-02-23 IL IL11275095A patent/IL112750A0/xx unknown
1997
- 1997-08-11 GR GR970402047T patent/GR3024403T3/el unknown

Also Published As

Publication number	Publication date
KR0148265B1 (ko)	1998-10-15
ATE156192T1 (de)	1997-08-15
DE68928222D1 (de)	1997-09-04
EP0778352A1 (en)	1997-06-11
ES2107412T3 (es)	1997-12-01
NO912328D0 (no)	1991-06-17
AU4829690A (en)	1990-07-10
HU216105B (hu)	1999-04-28
AU6301394A (en)	1994-06-30
IL92732A (en)	1997-06-10
EP0373960B1 (en)	1997-07-30
DK175630B1 (da)	2004-12-27
EP0373960A3 (en)	1991-04-10
GR3024403T3 (en)	1997-11-28
AU675520B2 (en)	1997-02-06
HUT58793A (en)	1992-03-30
PT92602B (pt)	1997-03-31
CA2005589C (en)	2001-02-06
BR8907830A (pt)	1991-10-22
RU2107729C1 (ru)	1998-03-27
CA2005589A1 (en)	1990-06-16
NO912328L (no)	1991-06-17
PT92602A (pt)	1990-06-29
DK110691D0 (da)	1991-06-11
JP3152927B2 (ja)	2001-04-03
WO1990006995A1 (en)	1990-06-28
FI99143B (fi)	1997-06-30
KR910700335A (ko)	1991-03-14
DK110691A (da)	1991-06-11
IL92732A0 (en)	1990-09-17
IL112750A0 (en)	1995-05-26
ZA899593B (en)	1990-09-26
NZ231815A (en)	1993-04-28
FI99143C (fi)	1997-10-10
FI912885A0 (fi)	1991-06-14
EP0373960A2 (en)	1990-06-20
DE68928222T2 (de)	1998-02-05

Publication	Publication Date	Title
NO311302B1 (no)	2001-11-12	Fremgangsmåte for å amplifisere et target RNA segment
CA2868618C (en)	2017-05-23	Compositions and methods for detecting west nile virus
JPH04503451A (ja)	1992-06-25	自己持続性、配列複製システム
US8574844B2 (en)	2013-11-05	Quantitative real-time assay for Noroviruses and Enteroviruses with built in quality control standard
US9702017B2 (en)	2017-07-11	HEV assay
US9080218B2 (en)	2015-07-14	HIV type and subtype detection
JP5754100B2 (ja)	2015-07-22	エンテロウイルス７１ｒｎａの検出方法および検出試薬
CN110945146A (zh)	2020-03-31	检测人类免疫缺陷病毒(hiv)的测定法
CA2582055C (en)	2014-04-08	Assay for detecting and quantifying hiv-1
US8258283B2 (en)	2012-09-04	Method for detection of HCV at the real time PCR with intercalating dye
US20040048246A1 (en)	2004-03-11	Oligonucleotide for detection of HIV-1 and detection method
AU2016202864B2 (en)	2018-02-15	Assay for detecting and quantifying HIV-1
JP2024517835A (ja)	2024-04-23	二重標的アッセイによりデルタ型肝炎ウイルスを検出するための組成物及び方法
US20040202998A1 (en)	2004-10-14	Method of amplifying or detecting HIV-1 RNA
US20050202416A1 (en)	2005-09-15	Mouse hepatitis virus detection
CN118339310A (zh)	2024-07-12	用于检测核酸序列负荷的组合物、试剂盒和方法
JP2019524123A (ja)	2019-09-05	核酸の増幅及び検出／定量の効率を改良するためのヘルパーオリゴヌクレオチド
JP2002125688A (ja)	2002-05-08	Ｃ型肝炎ウイルスの高感度検出のためのオリゴヌクレオチドおよび検出法

Legal Events

Date	Code	Title	Description
2010-01-18	MK1K	Patent expired